MANOPRESS: Severity of Fecal Incontinence and Manometric Values Using the Anopress® Device in Women

Sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (Other)
Overall Status
Completed
CT.gov ID
NCT05058326
Collaborator
(none)
41
1
12.4
3.3

Study Details

Study Description

Brief Summary

The purpose of this study is to stablish a correlation between fecal incontinence severity scales (Wexner & St. Mark's) and manometric values obtained using the Anopress® portable manometry and values obtained using endoanal ultrasound in women with fecal incontinence.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Portable endoanal manometry
  • Diagnostic Test: Endoanal ultrasound
  • Other: Incontinence severity scale questionaires

Detailed Description

The Anopress® portable anal manometry will be used to measure the pressures of the anal canal in different phases: rest, squeeze, strain and endurance.

All female patients referred with the diagnosis of fecal incontinence giving written informed consent will undergo a endoanal portable manometry at our outpatients clinics. They will be asked to fill out the severity questionaries (Sant Mark's and Wexner). All data will be collected for analysis.

An endoanal ultrasound will be performed in all patients to assess the sphincter integrity.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
41 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Severity of Fecal Incontinence and Manometric Values Using the Anopress® Device in Women
Actual Study Start Date :
Sep 20, 2020
Actual Primary Completion Date :
Oct 1, 2021
Actual Study Completion Date :
Oct 1, 2021

Arms and Interventions

Arm Intervention/Treatment
TEST GROUP

Women with fecal incontinence referred to outpatients clinic.

Diagnostic Test: Portable endoanal manometry
Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.

Diagnostic Test: Endoanal ultrasound
To assess the integrity of the anal canal.

Other: Incontinence severity scale questionaires
Wexner and St. Mark's scales.

Outcome Measures

Primary Outcome Measures

  1. Stablish a correlation between Wexner fecal incontinence severity scales and manometric values obtained using the Anopress® portable manometry in women with fecal incontinence [During the procedure]

    Spearman and Pearson correlation will be used to assess correlations between values

  2. Stablish a correlation between St. Mark's fecal incontinence severity scales and manometric values obtained using the Anopress® portable manometry in women with fecal incontinence [During the procedure]

    Spearman and Pearson correlation will be used to assess correlations between values

Secondary Outcome Measures

  1. Stablish a correlation between St.Mark's fecal incontinence severity scales and values obtained using endoanal ultrasound in women with fecal incontinence [During the procedure]

    Spearman and Pearson correlation will be used to assess correlations between values

  2. Stablish a correlation between Wexner fecal incontinence severity scales and values obtained using endoanal ultrasound in women with fecal incontinence [During the procedure]

    Spearman and Pearson correlation will be used to assess correlations between values

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with the clinical diagnosis of fecal incontinence

  • Age ≥ 18 years.

  • Informed consent signed by the patient and the researcher.

Exclusion Criteria:
  • Patients with psychiatric illnesses, addictions or any disorder that prevents understanding of the study.

  • Inability to read or understand the questionnaires.

  • Inability to read or understand any of the informed consent languages (Catalan, Spanish).

  • Any patient who, due to his medical characteristics, presents a high individual risk when being included and completing the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitari Dr. Josep Trueta de Girona Girona Catalunya Spain 17007

Sponsors and Collaborators

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
ClinicalTrials.gov Identifier:
NCT05058326
Other Study ID Numbers:
  • 052020
First Posted:
Sep 27, 2021
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022